Routine use of progesterone does not prevent miscarriageBMJ 2019; 367 doi: https://doi.org/10.1136/bmj.l5721 (Published 08 November 2019) Cite this as: BMJ 2019;367:l5721
- Rob Cook, clinical director1,
- Vaughan Thomas, clinical adviser2,
- Rachel Taft, clinical specialist1
- on behalf of the NIHR Dissemination Centre
- 1Bazian, Economist Intelligence Unit healthcare, London, UK
- 2Wessex Institute, University of Southampton, Southampton, UK
- Correspondence to R Cook
Coomarasamy A, Devall AJ, Cheed V, et al. A randomised trial of progesterone in women with bleeding in early pregnancy N Engl J Med 2019;380:1815-24.
This project was funded by the NIHR Health Technology Assessment Programme (project number 12/167/26).
To read the full NIHR Signal, go to https://discover.dc.nihr.ac.uk/content/signal-000792/miscarriage-not-prevented-by-routine-use-of-progesterone
Contributor: Yvonne Covell.
All authors contributed to development and review of this summary, as part of the wider NIHR Signals editorial team. RC is guarantor.
Disclaimer NIHR Signals are owned by the Department of Health and Social Care and are made available to the BMJ under licence. NIHR Signals report and comment on health and social care research but do not offer any endorsement of the research. The NIHR assumes no responsibility or liability arising from any error or omission or from the use of any information contained in NIHR Signals.
Permission to reuse these articles should be directed to firstname.lastname@example.org.
Competing interests The BMJ has judged that there are no disqualifying financial ties to commercial companies. The authors declare the following other interests: none.
Further details of The BMJ policy on financial interests is here: https://www.bmj.com/about-bmj/resources-authors/forms-policies-and-checklists/declaration-competing-interests